For in vitro diagnostic use. Others Elecsys GDF-15 IVD Elecsys® GDF-15 CPS_000476 08 946 779 190 8 946 779 190 08946779190 8946779190 08946779190 GDF-15 Elecsys cobas e 100 V2 Elecsys GDF-15 07613336170601 Reagents, kits 100 tests cobas e 411/601/602 true 07 028 172 190 7 028 172 190 07028172190 7028172190 07028172190 GDF-15 Elecsys E2G 100 Elecsys GDF-15 04015630940554 Reagents, kits 100 tests cobas e 402/801 true 08 946 809 190 8 946 809 190 08946809190 8946809190 08946809190 GDF-15 Elecsys E2G 100 V2 Elecsys GDF-15 07613336170618 Reagents, kits 100 tests cobas e 402/801 true 07 125 933 190 7 125 933 190 07125933190 7125933190 07125933190 GDF-15 Elecsys cobas e 100 Elecsys GDF-15 07613336102275 Reagents, kits 100 tests cobas e 411/601/602 true 08946779500 Elecsys GDF-15 en 2 FF000000047FDA0E FF000000041B260E 08946779190 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of Growth Differentiation Factor‑15 (GDF‑15) in human serum and plasma.The Elecsys GDF‑15 assay is intended as an aid in risk stratification of patients with Acute Coronary Syndrome (ACS) or Chronic Heart Failure (CHF). The Elecsys GDF‑15 assay is intended as an aid in risk prediction of major bleeding events of patients with Atrial Fibrillation (AF).The electrochemiluminescence immunoassay “ECLIA” is intended for use on Elecsys and cobas e immunoassay analyzers. en 07028172500 Elecsys GDF-15 en 4 FF000000036CA50E FF00000001C0550E 07028172190 2497 cobas e 801 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of Growth Differentiation Factor‑15 (GDF‑15) in human serum and plasma.The Elecsys GDF‑15 assay is intended as an aid in risk stratification of patients with Acute Coronary Syndrome (ACS) or Chronic Heart Failure (CHF). The Elecsys GDF‑15 assay is intended as an aid in risk prediction of major bleeding events of patients with Atrial Fibrillation (AF).The electrochemiluminescence immunoassay “ECLIA” is intended for use on the cobas e 801 immunoassay analyzer. en 08946809500 Elecsys GDF-15 en 3 FF000000047FB00E FF000000041A5A0E 08946809190 2497 cobas e 801 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of Growth Differentiation Factor‑15 (GDF‑15) in human serum and plasma.The Elecsys GDF‑15 assay is intended as an aid in risk stratification of patients with Acute Coronary Syndrome (ACS) or Chronic Heart Failure (CHF). The Elecsys GDF‑15 assay is intended as an aid in risk prediction of major bleeding events of patients with Atrial Fibrillation (AF).The electrochemiluminescence immunoassay “ECLIA” is intended for use on the cobas e 801 immunoassay analyzer. en 08946809500 Elecsys GDF-15 en 5 FF00000006FA180E FF0000000450900E 08946809190 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of Growth Differentiation Factor‑15 (GDF‑15) in human serum and plasma.The Elecsys GDF‑15 assay is intended as an aid in risk stratification of patients with Acute Coronary Syndrome (ACS) or Chronic Heart Failure (CHF). The Elecsys GDF‑15 assay is intended as an aid in risk prediction of major bleeding events of patients with Atrial Fibrillation (AF).The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en

User Profile

Select your user profile

Elecsys^® GDF-15

Overview

Detailed Specifications

Ordering Information

Compatible Instruments

Technical Documents